A Safety Analysis of Programmed Death 1 Pathway Inhibitors in Patients With Solid Tumor Malignancies and Preexisting Autoimmune Disease-Reference-Cited by-同舟云学术

A Safety Analysis of Programmed Death 1 Pathway Inhibitors in Patients With Solid Tumor Malignancies and Preexisting Autoimmune Disease

Published:2022-06-08 Issue:7 Volume:28 Page:338-345
ISSN:1536-7355
Container-title:JCR: Journal of Clinical Rheumatology
language:en
Short-container-title:J Clin Rheumatol

Author:

Higgins Jordyn Paige,Trinh Anh Viet,Watson Marley L.,Beardslee Tyler,Goyal Subir,Kudchadkar Ragini,Pakkala Suchita,Waltuck Jonathan,Momary Kathryn,Byers Kristina F.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Rheumatology

Reference25 articles.

2. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells;Immunol Cell Biol,2018

3. Cancer and autoimmune diseases;Autoimmun Rev,2017

4. Autoimmunity and cancer, the paradox comorbidities challenging therapy in the context of preexisting autoimmunity;J Interferon Cytokine Res,2019

5. Prevalence of autoimmune disease among patients with lung cancer: implications for immunotherapy treatment options;JAMA Oncol,2016

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety of nivolumab monotherapy in five cancer types: pooled analysis of post-marketing surveillance in Japan;International Journal of Clinical Oncology;2024-06-06

2. Predictive Factors in Metastatic Melanoma Treated with Immune Checkpoint Inhibitors: From Clinical Practice to Future Perspective;Cancers;2023-12-24

3. Immune checkpoint inhibitors: maximizing benefit whilst minimizing toxicity;Expert Review of Anticancer Therapy;2023-05-22